Connect Biopharma Holdings Ltd Stock Price, News & Analysis

Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical firm focused on T cell-driven therapies, will present at several conferences in February and March 2023. Notable events include the SVB Securities Global Biopharma Conference on February 15 at 4:10 PM Eastern and the BioCom Global Partnering and Investor Conference from February 28 to March 2. The company is advancing a pipeline of therapies for chronic inflammatory diseases, targeting conditions like atopic dermatitis, asthma, and ulcerative colitis. Key product candidates include CBP-201 and CBP-307.

Connect Biopharma (CNTB) announced a revised timeline for its global Phase 3 program of CBP-201 in atopic dermatitis, now expected to start after securing partnerships. The cash runway is projected to extend into at least 2025, allowing ample time for ongoing trials and potential partnerships. The pivotal trial in China is on track, with Stage 2 completion expected in H2 2023. The company is also moving forward with CBP-307 in ulcerative colitis, with a Phase 2 maintenance phase expected to complete soon. Positive interactions with regulatory bodies are planned for early 2023.

Connect Biopharma (Nasdaq: CNTB) will present a corporate update led by CEO Zheng Wei, PhD, on January 9, 2023, at 9:00 am PST during the Biotech Showcase. The event takes place in San Francisco from January 9-11, 2023. Key executives, including CFO Steven Chan and CMO Chin Lee, will also be available for investor meetings. Connect Biopharma focuses on developing T cell-driven therapies for inflammatory diseases, with product candidates like CBP-201 for atopic dermatitis, CBP-307 for ulcerative colitis, and CBP-174 for pruritus.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) received a letter from Nasdaq on November 28, 2022, indicating that its American Depositary Shares (ADSs) have been below the minimum bid price of $1.00 for 30 consecutive business days. The company has until May 29, 2023, to regain compliance with Listing Rule 5550(a)(2). If compliance is not achieved, it may qualify for an additional 180-day period after transitioning to the Nasdaq Capital Market. The letter is a notification only and does not affect the trading of ADSs.

Connect Biopharma Holdings Limited (Nasdaq: CNTB), a biopharmaceutical firm focused on T cell-driven therapies for inflammatory diseases, announced its participation in several upcoming investor and scientific conferences. Key events include the 6th Annual Dermatology Drug Development Summit in Boston (Nov 1-3), where CEO Zheng Wei will present on Nov 2, and others through December, including the Piper Sandler Healthcare Conference in New York. The company continues to develop promising therapies, including its lead candidate targeting IL-4Rα for atopic dermatitis.

Connect Biopharma (Nasdaq: CNTB) announced positive topline results from a pivotal trial of its lead candidate, CBP-201, for moderate-to-severe atopic dermatitis in 255 patients in China. The primary endpoint, achieving an IGA of 0 or 1 at Week 16, was met significantly (30.3% for CBP-201 vs. 7.5% placebo, p < 0.001). Key secondary endpoints also showed significant efficacy. CBP-201 was well tolerated, with safety profiles similar to placebo. The company plans to advance discussions for a New Drug Application (NDA) in China.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) will report topline results from its pivotal trial of lead candidate CBP-201 for moderate-to-severe atopic dermatitis (AD) in China. This highly anticipated announcement is set for tomorrow, October 4, 2022, and will be followed by a conference call and webcast at 5:30 a.m. PDT/8:30 a.m. EDT. The trial results will be significant for investors closely monitoring the company’s progress in treating inflammatory diseases.

Connect Biopharma (CNTB) announced key developments and financial results for the six months ending June 30, 2022. The company expects to report top-line data for its lead drug CBP-201 in atopic dermatitis in October 2022, ahead of schedule. They completed a global Phase 2b trial for CBP-201 showing positive efficacy, and R&D expenses rose to RMB 340.8 million due to ongoing clinical trials. The net loss was RMB 401.3 million, a decrease from the previous year's loss. The company has sufficient funds to support operations into at least 2024.